Dr. Adil I. Daud, MD

Dr. Daud practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Daud's NPI, 1699706812, was assigned on July 5, 2006. Dr. Daud graduated from Government Medical College Nagpur in 1987. Dr. Daud's Florida license number on file is ME85033.

Dr. Daud's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Daud's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Daud to 3 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Daud practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Daud's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Daud is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Daud's licenses on file in 4 states: Florida, District of Columbia, California and New York.

CMS data shows 571 Medicare services from Dr. Daud across 3 procedure codes in 2024, all of them office visits, for 224 Medicare patients. Medicare paid $69,926 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 224 Medicare patients who saw Dr. Daud in 2024. The largest group is 65 to 74, with 96 patients. 65% of them have high cholesterol, and 63% have high blood pressure. 11% are also on Medicaid. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Daud's median patient age at 72, with 37% women.

In 2024, Dr. Daud wrote 186 Medicare Part D claims for 50 patients. 76% of them were for generic drugs. CMS names the drug for 60 of them, across 3 drugs with 11 or more claims each, at $1,835 in total drug cost. In 2023, CMS named 53 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Daud for performance year 2024, reported as part of a group. Dr. Daud accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Daud as offering telehealth.

Dmand AI links 106 papers to Dr. Daud, published from 2006 to 2022. 2015 was the busiest year, with 9. The most frequent topics are Melanoma, Skin Neoplasms and Antineoplastic Agents. Dr. Daud has published most often in Clin Cancer Res. Dr. Daud's most frequent co-authors are Omid Hamid, MD, Alain Algazi, MD and Pamela N. Munster, MD.

CMS Open Payments shows 291 general payments to Dr. Daud from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Merck Sharp & Dohme Corporation paid the most, $123,228. It also lists 16 research payments totaling $18,979 from 2016 to 2025, naming 3 clinical trials.

Dr. Daud serves on SWOG melanoma.

Dr. Daud graduated from Government Medical College Nagpur in 1987. Dr. Daud is a member of ASCO.

Dr. Daud is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.